Broadcast Date: May 13, 2022
Time: 8:00 am PT, 11:00 am ET, 17:00 CET
Cell line development (CLD) is a critical aspect of the drug discovery process, and nowhere is this more apparent than through the use of Chinese hamster ovary (CHO) cells. These cells have transformed modern therapeutic antibody production due to the cell line’s inherent scalability benefits, ability to produce proteins with the necessary mammalian posttranslational modifications, large yield protein titers, and a longstanding regulatory record. However, while biomanufacturers have made great strides toward increasing the production outputs from these cell lines, data supporting the stability of secreted proteins during CLD is scarce. Bridging the gap between CLD and developability will allow biomanufacturers to pre-screen samples for stability after cell secretion.
In this GEN webinar, our distinguished guest, Dr. Bernardo Cordovez, will give us more insight into a novel platform technology that delivers low volume, high-throughput subvisible particle imaging counting, sizing, and identification. The Aura PTx™ is a complete protein therapeutic stability solution that enables characterization of subvisible particle aggregates from CHO cell line development, thru developability assessment down to product release—providing investigators a deeper understanding of the physical instabilities of the biologic in question.
A live Q&A followed the presentation, offering a chance to pose questions to our expert panelist.
Produced with support from: